Automated And Closed Cell Therapy Processing Systems Market To Reach $7.44 Billion By 2033

Automated And Closed Cell Therapy Processing Systems Market Growth & Trends

The global automated and closed cell therapy processing systems market size is anticipated to reach USD 7.44 billion by 2033, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 20.73% from 2026 to 2033. Market players are making significant investments to introduce an automated process system as a viable strategy to accelerate their cell therapy product development process, thereby driving market growth.

The expansion of GMP manufacturing facilities further supports the implementation of automated processes for commercial operations. In addition, the wide application scope of single-use disposable tubing sets and bags also facilitates automated processing of therapy R&D. Moreover, key entities are undertaking strategies for effective implementation of automation technology in manufacturing labs resulting in lucrative revenue growth.

The rapid growth in the cases of COVID-19 is anticipated to play a vital role in the market growth. The pandemic has led to an increased focus on automation technologies. Moreover, the companies emphasized raising funds with an aim to develop advanced therapies and regenerative medicines to fight against COVID-19. Industry players are also concentrating on the development of new therapies, such as stem cell therapy, natural killer cell therapy, exosomes, and others.

 Request a free sample copy or view report summary: Automated And Closed Cell Therapy Processing Systems Market Report

Automated And Closed Cell Therapy Processing Systems Market Report Highlights

• The separation segment dominated the market and accounted for a share of 31.72% in 2025 and is expected to grow at the fastest CAGR of 20.7% over the forecast period. 

• The non stem cell therapy segment accounted for the largest market revenue share in 2025 and is expected to grow at the fastest CAGR over the forecast period. 

• The pre-commercial/ R&D scale segment accounted for the largest market revenue share in 2025 and is expected to grow at the fastest CAGR over the forecast period. 

• North America automated and closed cell therapy processing systems market held the largest share of 50.9% in 2025 owing to the increasing demand for integrated solutions that streamline the storage, transportation, and processing of cell and gene therapies, enhancing the efficiency of clinical trials and commercialization efforts.

Automated And Closed Cell Therapy Processing Systems Market Segmentation

Grand View Research has segmented the global automated and closed cell therapy processing systems market report based on workflow, type, scale, and region:

Automated And Closed Cell Therapy Processing Systems Workflow Outlook (Revenue, USD Million, 2021 - 2033)

• Separation

• Expansion

• Apheresis

• Fill- Finish

• Cryopreservation

• Others

Automated And Closed Cell Therapy Processing Systems Type Outlook (Revenue, USD Million, 2021 - 2033)

• Stem Cell Therapy

• Non Stem Cell Therapy

Automated And Closed Cell Therapy Processing Systems Scale Outlook (Revenue, USD Million, 2021 - 2033)

• Pre-Commercial/ R&D Scale

• Commercial Scale

Automated And Closed Cell Therapy Processing Systems Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List Of Key Players in the Automated And Closed Cell Therapy Processing Systems Market

• Miltenyi Biotec

• Lonza

• Fresenius Kabi AG

• Danaher Corporation

• BioSpherix, LLC

• Terumo Corporation

• Sartorius AG

• ThermoGenesis Holdings, Inc.

• CELLARES

• Thermo Fisher Scientific Inc.